← Human Trials & Peer-Reviewed Studies
Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial
Plain-language guide to PMID 17162712 (2006): double-blind randomized controlled trial of Goserelin in 31 women.
Key Facts
- PMID
- 17162712
- Journal
- Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Franke HR et al. (4 authors)
- DOI
- 10.1080/09513590601015101
What This Study Did, in Plain Language
What Was Tested
Researchers studied Goserelin in this randomized controlled trial publication.
To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women.
Who Took Part
According to the abstract, 31 women were involved.
The age groups tagged for this paper are middle-aged adults, women only.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Goserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Goserelin study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Goserelin could be set against what happens without it.
The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score).
What Was Measured
The subject headings attached to it are Antineoplastic Agents, Hormonal, Bone Density, Climacteric, Drug Combinations, Estradiol, Goserelin and Hormone Replacement Therapy.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Goserelin in 31 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2006 (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology), a journal based in England.
More context: the Goserelin compound page, all human trials.
Our Notes on the Compound
Goserelin: A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.